MicroRNA145 targets BNIP3 and suppresses prostate cancer progression

Cancer Research

Volumn 70, Issue 7, 2010, Pages 2728-2738

  Chen, Xueqin ^a   Gong, Jing ^a   Zeng, Hao ^b   Chen, Ni ^a   Huang, Rui ^a   Huang, Ying ^a   Nie, Ling ^a   Xu, Miao ^a   Xia, Juan ^a   Zhao, Fang ^c   Meng, Wentong ^a   Zhou, Qiao ^a  

^a SICHUAN UNIVERSITY   (China)

^b Department of Urology ^*  (China)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; MICRORNA; MICRORNA145; PROTEIN BNIP3; PROTEIN P53; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; REPORTER GENE; TUMOR GROWTH;

3' UNTRANSLATED REGIONS; ADENOCARCINOMA; ADENOVIRIDAE; APOPTOSIS INDUCING FACTOR; CELL LINE, TUMOR; DISEASE PROGRESSION; DOWN-REGULATION; GENETIC VECTORS; HUMANS; MALE; MEMBRANE PROTEINS; MICRORNAS; MUTAGENESIS, SITE-DIRECTED; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 77950818716     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3718     Document Type: Article

References (49)

1. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 20066:857-866
2. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 20066:259-269
3. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 200625:6188-6196
4. Michael MZ, SM OC, van Hoist Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 20031:882-891
5. lorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 200767:8699-8707
6. lorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 200565:7065-7070
7. 7. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sei 2007; 98:1914-1920 (Pubitemid 350002197)
8. Schepeler T, Reinert JT, Ostenfeld MS, et al. Diagnostic and prognostic microRNAs in stage Il colon cancer. Cancer Res 2008; 68:6416-6424
9. 9. Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer. Cancer Res 2007;67:6130-6135 (Pubitemid 47037493)
10. Ozen M, Creighton CJ, Ozdemir M, lttmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 200827:1788-1793
11. 11. Boyd JM, Malstrom S, Subramanian T, et al. Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins. Cell 1994;79:341-351 (Pubitemid 24324923)
12. 12. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 2001;61:6669-6673 (Pubitemid 32896483)
13. Burton TR, Eisenstat DD, Gibson SB. BNIP3 (Bcl-2 19 kDa interacting protein) acts as transcriptional repressor of apoptosis-inducing factor expression preventing cell death in human malignant gliomas. J Neurosci 200929:4189-4199
14. 14. Giatromanolaki A, Koukourakis Ml, Sowter HM, et al. BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. Clin Cancer Res 2004;10:5566-5571 (Pubitemid 39100497)
15. 15. Kothari S, Cizeau J, McMillan-Ward E, et al. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 2003;22:4734-4744 (Pubitemid 36976448)
16. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 200533:e179.
17. Diederichs S, Haber DA. Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res 200666:6097-6104
18. Chen N, Chen X, Huang R, et al. BCL-xL is a target gene regulated by hypoxia-inducible factor-1 {a}. J Biol Chem 2009284:10004-10012
19. Sempere LF, Christensen M, Silahtaroglu A, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 200767:11612-11620
20. 20. He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998; 95:2509-2514 (Pubitemid 28145972)
21. Sachdeva M, Zhu S, Wu F, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A 2009106:3207-3212
22. 22. Carroll AG, Voeller HJ, Sugars L, Gelmann EP. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993; 23:123-134 (Pubitemid 23289894)
23. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 199151:4716-4720
24. 24. Gramantieri L, Ferracin M, Fomari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007;67:6092-6099 (Pubitemid 47037488)
25. 25. Subramanian S, Lui WO, Lee CH, et al. MicroRNA expression signature of human sarcomas. Oncogene 2008;27:2015-2026 (Pubitemid 351442735)
26. Wang X, Tang S, Le SY, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE 20083:e2557.
27. Dyrskjot L, Ostenfeld MS, Bramsen JB, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 200969: 4851-4860
28. Takagi T, lio A, Nakagawa Y, et al. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology 200977: 12-21.
29. Chen HC, Chen GH, Chen YH, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer 2009100:1002-1011
30. 30. Slabý O, Svoboda M, Fabian P, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007;72:397-402. (Pubitemid 351238155)
31. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 20069:189-198
32. 32. Shi B, Sepp-Lorenzino L, Prisco M, et al. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 2007;282:32582-32590 (Pubitemid 350159311)
33. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 200666:7390-7394
34. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009137:647-658
35. Wang S, Bian C, Yang Z, et al. miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol 200934:1461-1466
36. 36. Vande Velde C, Cizeau J, Dubik D, et al. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 2000;20:5454-5468 (Pubitemid 30482883)
37. Sowter HM, Ferguson M, Pym C, et al. Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. J Pathol 2003; 201:573-580
38. 38. Burton TR, Henson ES, Baijal P, Eisenstat DD, Gibson SB. The procell death Bcl-2 family member, BNIP3, is localized to the nucleus of human glial cells: implications for glioblastoma multiforme tumor cell survival under hypoxia. Int J Cancer 2006;118:1660-1669 (Pubitemid 43376429)
39. 39. Leo C, Horn LC, Hockel M. Hypoxia and expression of the proapoptotic regulator BNIP3 in cervical cancer. Int J Gynecol Cancer 2006;16:1314-1320 (Pubitemid 43886763)
40. 40. Giatromanolaki A, Koukourakis Ml, Gatter KC, Harris AL, Sivridis E. BNIP3 expression in endometrial cancer relates to active hypoxia inducible factor 1α pathway and prognosis. J Clin Pathol 2008;61: 217-220 (Pubitemid 351218884)
41. 41. Bacon AL, Fox S, Turley H, Harris AL. Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer. Oncogene 2007;26:132-141 (Pubitemid 46067338)
42. 42. Okami J, Simeone DM, Logsdon CD. Silencing of the hypoxiainducible cell death protein BNIP3 in pancreatic cancer. Cancer Res 2004;64:5338-5346 (Pubitemid 39006554)
43. 43. Murai M, Toyota M, Suzuki H, et al. Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin Cancer Res 2005;11:1021-1027 (Pubitemid 40175749)
44. Tan EY, Campo L, Han C, et al. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clin Cancer Res 200713:467-474
45. Barbero S, Mielgo A, Torres V, et al. Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis. Cancer Res 200969:3755-3763
46. Suzuki HI, Yamagata K, Sugimoto K, et al. Modulation of microRNA processing by p53. Nature 2009460:529-533
47. Gurova KV, Rokhlin OW, Budanov AV, et al. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res 200363:2905-2912
48. Zheng L, Wang F, Qian C, et al. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines. Hum Mutat 200627:1062-1063
49. s49. Stambolsky P, Weisz L, I, et al. Regulation of AIF expression by p53. Cell Death Differ 200613:2140-2149